ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Aeterna Zentaris Inc

Aeterna Zentaris Inc (AEZS)

2.19
0.11
(5.29%)
Closed March 29 04:00PM
2.19
0.00
(0.00%)
After Hours: 06:45PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.19
Bid
2.15
Ask
2.18
Volume
49,615
2.01 Day's Range 2.19
1.3601 52 Week Range 3.38
Market Cap
Previous Close
2.08
Open
2.04
Last Trade
54
@
2.18
Last Trade Time
Financial Volume
$ 105,088
VWAP
2.1181
Average Volume (3m)
16,982
Shares Outstanding
4,855,876
Dividend Yield
-
PE Ratio
-0.47
Earnings Per Share (EPS)
-4.68
Revenue
5.64M
Net Profit
-22.73M

About Aeterna Zentaris Inc

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license a... AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Toronto, Ontario, Can
Founded
1970
Aeterna Zentaris Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AEZS. The last closing price for Aeterna Zentaris was $2.08. Over the last year, Aeterna Zentaris shares have traded in a share price range of $ 1.3601 to $ 3.38.

Aeterna Zentaris currently has 4,855,876 shares outstanding. The market capitalization of Aeterna Zentaris is $10.63 million. Aeterna Zentaris has a price to earnings ratio (PE ratio) of -0.47.

AEZS Latest News

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to...

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into...

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased...

Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to...

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and...

Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro

Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value propositionMore information and materials...

Form F-1 - Registration statement for certain foreign private issuers

  As filed with the Securities and Exchange Commission on February 15, 2024   Registration No. 333-___________       UNITED STATES SECURITIES AND EXCHANGE...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.199.522.191.96120192.02572111CS
40.2814.65968586391.912.391.83254072.02492629CS
120.2915.26315789471.92.391.68169821.99008938CS
26-0.22-9.128630705392.412.521.3601147531.96065609CS
52-0.57-20.6521739132.763.381.3601130582.34584331CS
1560.9982.51.25.90.16457032660.7329251CS
260-1.88-46.19164619164.075.90.164518510651.14833108CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

AEZS Discussion

View Posts
at14tao at14tao 2 weeks ago
Great, now another reverse split coming. Now my .5 shares at $25,000/share will become .1 shares at $125,000/share.... lol but hey, I'll get .1 warrant to help cover my losses.... lol
👍️0
Awl416 Awl416 2 weeks ago
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
👍️0
ernie44 ernie44 2 months ago
Russian Sub runs aground in America

👍️0
ernie44 ernie44 4 months ago
ok this is my last one


👍️0
ernie44 ernie44 4 months ago
SHATNERS early days (ca. 1963 ) in show bizz




👍️0
ernie44 ernie44 6 months ago
AEZZZZZZZZZZZZZZZZZZZZZZZZZS SUCKS

👍️0
ernie44 ernie44 6 months ago
ZZZZZZZZZZZZZZZZZZZZZZ....................................................................................................................................................NO BODY SELLING EITHER......................................................................................






👍️0
ernie44 ernie44 6 months ago
or head north to escape the heat




👍️0
ernie44 ernie44 6 months ago
strike it rich like the Bev, Hillbullies

👍️0
ernie44 ernie44 9 months ago
MIGHT BE ON THIS LIST SOON

https://www.sec.gov/divisions/enforce/delinquent/delinqindex.htm
👍️0
ernie44 ernie44 9 months ago
think this one is done..... ?????
👍️0
ernie44 ernie44 12 months ago
were they trying to eliminate COVID -9.or what did Toronto think they are a foreign issuer...duhh
👍️0
livendi livendi 12 months ago
exactly,i have no idea what we were thinking,live and learn bro,God bless and good luck
👍️0
Patrickwan1 Patrickwan1 12 months ago
Nearly all management had been in this company for many many years.. seems dead wood already .. milking this company!
👍️0
Patrickwan1 Patrickwan1 12 months ago
This company has been listed for more than 30 years! But nothing achieved, really!
👍️0
livendi livendi 12 months ago
me too bro,God bless and good luck
👍️0
Patrickwan1 Patrickwan1 12 months ago
I should have known this is crab as there is No financial institution holding! This management has milk from shareholders for 30+ years !
👍️0
livendi livendi 12 months ago
sorry bro,put this pos behind u like i did,maybe it will jump a little on pedi approval but who knows how long that will take,only chance for this is other uses for macrilen but at the pace klauss and aezs goes that will take a decade,we should have known by aezs past,i was up 85k and ended up losing 15k so i feel your frustration,God bless and good luck
👍️0
Patrickwan1 Patrickwan1 12 months ago
Wtf, E&Y declined the reappointment as auditors !!
👍️0
ernie44 ernie44 1 year ago
they will try---- its not like a run on the stock.............


👍️0
Patrickwan1 Patrickwan1 1 year ago
Shorters are bastard earning nothing in shorting this kind of stock!!
👍️0
livendi livendi 1 year ago
what a f disaster,God bless and good luck
👍️0
Patrickwan1 Patrickwan1 1 year ago
Very bad… 99% holdings in hand of public!!!
👍️0
ernie44 ernie44 1 year ago
Confuscios say ''buy low---- sell high''






👍️0
Patrickwan1 Patrickwan1 1 year ago
Over 30 years company…Only 11 employees and very few financial institutional investors …very bad…
👍️0
livendi livendi 1 year ago
to boot klauss is making near 750k a yr for cratering aezs pps,sma aezs and klauss,God bless all
👍️0
livendi livendi 1 year ago
what a f disaster this has turned out to be,we all make mistakes and this is 1 for both of us,f aholes take forever to get things done,novo backed out of deal.this could easily go down below a buck again,sorry but we both fd up with this pos,tax rt off is all,and we all make mistakes sometimes,should have looked at past performance also,since its inception all it has done is go down,unless macrilen can be used for other things besides a test they got 0,sorry for our losses,God bless and good luck
👍️0
Patrickwan1 Patrickwan1 1 year ago
A crook..
👍️0
Patrickwan1 Patrickwan1 1 year ago
No more oral COVID pill… a spam..
👍️0
ernie44 ernie44 1 year ago
this stock seems to ALWAYS come back in SPADES
👍️0
ernie44 ernie44 1 year ago
a good friend of mine had 2 of those Citroens... a engineered marvel

👍️0
ernie44 ernie44 1 year ago
1950's were the days of the Jackal's

👍️0
Patrickwan1 Patrickwan1 1 year ago
Instead of giving updates, company chooses to publish those old information which already published .. it is not alert at all! It just so amazing a company keeps on publishing old information not bothering how public would expect.
👍️0
ernie44 ernie44 1 year ago
getting alerts every day now on AEZS
👍️0
ernie44 ernie44 1 year ago
on the list ???


Listing of Company Delinquent Filings Update
10/04/2022
You are subscribed to receive Listings of Company Delinquent Filings from the Securities and Exchange Commission.

This information has recently been updated and is now available.

https://www.sec.gov/divisions/enforce/delinquent/delinqindex.htm
👍️0
ernie44 ernie44 2 years ago
BOND JAMES couldnt save it,,, but James BLOND will ,,,,,with secret tricks


watch
👍️0
Elgordo84 Elgordo84 2 years ago


On November 16, 2020, the Company announced that it had entered into the Novo Amendment related to the development and commercialization of macimorelin. Novo is currently marketing macimorelin in the U.S. under the trade name Macrilen™ for the diagnosis of AGHD. Aeterna, in collaboration with Novo, is currently developing the expanded use of macimorelin for the diagnosis of CGHD, an area of significant unmet medical need.

On December 7, 2020, the Company entered into an exclusive licensing agreement with Consilient Health Limited (“CH” or “Consilient”) for the commercialization of macimorelin in the European Economic Area and the United Kingdom. In December 2021, the Department of Health and Social Care in the United Kingdom approved a list price which triggered a $226 (€0.2 million) pricing milestone payment from CH to the Company. In Germany, a list price was approved on June 15, 2022 which triggered a second $226 (€0.2 million) pricing milestone payment from CH to the Company. We shipped initial batches of macimorelin (Ghryvelin®) to Consilient in the first quarter of 2022. Consilient launched the product in the United Kingdom, Sweden and Denmark in May 2022 and launches in Germany and Finland are scheduled for July 2022.

We entered into license and supply agreements with NK Meditech Ltd. (“NK”), a subsidiary of PharmBio Korea, effective November 30, 2021, and a distribution and commercialization agreement with ER Kim Pharmaceuticals Bulgaria Food (“ER-Kim”), effective February 1, 2022. The agreements with NK are related to the development and commercialization of macimorelin for the diagnosis of AGHD and CGHD in the Republic of Korea, while the agreement with ER-Kim is related to the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries.

On April 19, 2022, we announced that European Patent Office had issued a patent providing intellectual property protection of macimorelin in 27 countries within the European Union as well as additional European non-EU countries, such as the UK and Turkey, for macimorelin (Ghryvelin®; Macrilen™) for use to diagnose GHD in adults.

Follow the money folks!!!

#ELGORDODAMUS
$AEZS
👍️0
Elgordo84 Elgordo84 2 years ago
Could this become a $100 ticker
In the next 6-18 months
It’s been on my radar for over a year
Let see how it plays out.

#ELGORDODAMUS
$AEZS
👍️0
ernie44 ernie44 2 years ago
yah, when you got a billion shares--there are lots of reverse splits to be done --- ..................................................................
👍️0
ernie44 ernie44 2 years ago
AEZS wants to be a BLUE chip outfit
👍️0
Patrickwan1 Patrickwan1 2 years ago
Further adjourning shareholders meeting. Klaus, don’t waste your time. It’s time to consider AEZS to buy back some share from the market. Or else AEZS is facing delisting..
👍️0
Patrickwan1 Patrickwan1 2 years ago
Really pk..
👍️0
Patrickwan1 Patrickwan1 2 years ago
Just a pump & dump.. really crab!
👍️0
Patrickwan1 Patrickwan1 2 years ago
Damn…
👍️0
livendi livendi 2 years ago
patrick i have to be honest,i sold because i needed the money to fix driveway,took a big hit but didnt have a choice really,God bless and good luck,sorry we were wrong about this 1 ,i dont know whats going to happen with this,if catalysts come to fruition it will jump back but at the rate they are going it could take a while and rs are almost always bad,God bless and good luck bro
👍️0
Patrickwan1 Patrickwan1 2 years ago
The share consolidation did not get shareholders approval… going to be delisted or going to pink… AEZS has sufficient cash to buy back 100 million shares and still leaving plenty amount for R&D. Buy back shares also show management is confident on its current candidates! AEZS is very risky facing delisted! What have you voted on this?
👍️0
livendi livendi 2 years ago
no way to test kids for ghd,no way,after approval it will help a lot,again no way to test kids for ghd,0 competition,what sucks is the delay because of putins war and the other catalysts takng forever like the covid pill,no urgency,sh feel it,check out tsoi,cant recommend per rules but check it out
👍️0
Patrickwan1 Patrickwan1 2 years ago
Shorters keep shorting this stock in view of RS. Management is bad and this stock is crab!
👍️0
Patrickwan1 Patrickwan1 2 years ago
Pedi test is just a test, not a drug.., not much value, right?!
👍️0
livendi livendi 2 years ago
sorry patrickt,the pedi test final trial being delayed has killed us along with all the other catalysts taking forever,God bless bro
👍️0

Your Recent History

Delayed Upgrade Clock